Breaking News Instant updates and real-time market news.

ALKS

Alkermes

$57.93

0.71 (1.24%)

04:55
05/19/17
05/19
04:55
05/19/17
04:55

Alkermes management to meet with JPMorgan

Meeting to be held in Los Angeles on May 19 hosted by JPMorgan.

  • 19

    May

  • 06

    Jun

  • 08

    Jun

ALKS Alkermes
$57.93

0.71 (1.24%)

04/27/17
JEFF
04/27/17
NO CHANGE
Target $69
JEFF
Buy
Jefferies trims Alkermes target to $69 after Q1 miss
Jefferies analyst Biren Amin attributes Alkermes' Q1 miss to Vivitrol and lowered his price target for the shares to $69 from $70. The analyst keeps a Buy rating on the name. Management blamed inventory destocking for the weaker than expected Vivitrol sales and reiterated the drug's outlook for 2017, Amin tells investors in a post-earnings research note. He expects the challenges Aristada observed from higher gross to net rebates in the quarter to stabilize in the second half of 2017.
04/27/17
JPMS
04/27/17
NO CHANGE
Target $78
JPMS
Overweight
JPMorgan keeps Overweight rating on Alkermes after Q1 miss
JPMorgan analyst Cory Kasimov attributes Alkermes' Q1 miss to "commercial seasonality and pricing." He points out management reiterated 2017 guidance and highlighted that underlying trends for both Aristada and Vivitrol remain strong. The analyst continues to believe the legacy base business, combined with the growth potential of Vivitrol and Aristada and the optionality of the wholly owned late-stage pipeline, offers an "attractive combo" for investors. Kasimov keeps an Overweight rating on Alkermes with a $78 price target.
05/01/17
FBCO
05/01/17
NO CHANGE
Target $70
FBCO
Outperform
Alkermes price target lowered to $70 from $78 at Credit Suisse
Credit Suisse analyst Vamil Divan lowered his price target for Alkermes to $78 from $70 after Q1 results. The analyst reiterates an Outperform rating, and notes that his enthusiasm on Alkermes remains driven by the upside he expects from Vivitrol in the near to mid-term and then the pipeline over time.
05/18/17
LEER
05/18/17
NO CHANGE
LEER
Outperform
Leerink sees 'multiple approvability questions' for Alkermes in depression
Leerink analyst Paul Matteis believes "multiple approvability questions" remain after Alkermes this morning presented additional clinical data for ALKS 5461 in treatment resistant depression. The FDA's acceptance of a novel trial design and tweaked clinical endpoint are among the outstanding issues, Matteis tells investors in a research note. Today's data are unlikely to "materially shift the debate in the short term," the analyst adds. Matteis, however, remains "encouraged by the breadth of precedent for FDA flexibility in psychiatry" ahead of an ALKS 5461 new drug application filing in the second half of the year. He reiterates an Outperform rating on Alkermes. The stock in afternoon trading is up 57c to $57.79.

TODAY'S FREE FLY STORIES

ROKU

Roku

$21.87

-0.16 (-0.73%)

07:25
10/23/17
10/23
07:25
10/23/17
07:25
Initiation
Roku initiated  »

Roku initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Nov

TSRO

Tesaro

$116.40

0.89 (0.77%)

, CLVS

Clovis

$77.50

0.73 (0.95%)

07:24
10/23/17
10/23
07:24
10/23/17
07:24
Initiation
Tesaro, Clovis initiated  »

Tesaro initiated with an…

TSRO

Tesaro

$116.40

0.89 (0.77%)

CLVS

Clovis

$77.50

0.73 (0.95%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Oct

  • 06

    Nov

  • 08

    Nov

NCNA

NuCana

$14.08

-0.3 (-2.09%)

07:23
10/23/17
10/23
07:23
10/23/17
07:23
Initiation
NuCana initiated  »

NuCana initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

07:23
10/23/17
10/23
07:23
10/23/17
07:23
General news
Futures higher ahead of buy week of earnings »

Stock futures are…

AIMT

Aimmune

$25.66

-0.06 (-0.23%)

, DBVT

DBV Technologies

$48.07

0.92 (1.95%)

07:23
10/23/17
10/23
07:23
10/23/17
07:23
Recommendations
Aimmune, DBV Technologies analyst commentary  »

Aimmune price target…

AIMT

Aimmune

$25.66

-0.06 (-0.23%)

DBVT

DBV Technologies

$48.07

0.92 (1.95%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Nov

FL

Foot Locker

07:23
10/23/17
10/23
07:23
10/23/17
07:23
Downgrade
Foot Locker rating change  »

Foot Locker downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TXN

Texas Instruments

$95.18

1.73 (1.85%)

07:23
10/23/17
10/23
07:23
10/23/17
07:23
Recommendations
Texas Instruments analyst commentary  »

Texas Instruments price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

JPM

JPMorgan

$99.51

1.4 (1.43%)

07:22
10/23/17
10/23
07:22
10/23/17
07:22
Periodicals
JPMorgan, Mosaic Smart Data partner to boost fixed-income trading, Reuters says »

JPMorgan has teamed up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 02

    Nov

  • 05

    Nov

  • 27

    Feb

  • 13

    Apr

  • 14

    Jul

  • 12

    Oct

CLVS

Clovis

$77.50

0.73 (0.95%)

07:21
10/23/17
10/23
07:21
10/23/17
07:21
Initiation
Clovis initiated  »

Clovis initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Nov

BIIB

Biogen

$338.10

-4.32 (-1.26%)

, ESALY

Eisai

$53.38

-0.25 (-0.47%)

07:19
10/23/17
10/23
07:19
10/23/17
07:19
Hot Stocks
Biogen, Eisai expand existing collaboration agreement »

Eisai Co., Ltd. (ESALY)…

BIIB

Biogen

$338.10

-4.32 (-1.26%)

ESALY

Eisai

$53.38

-0.25 (-0.47%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

  • 25

    Oct

NITE

Nightstar Therapeutics

$19.00

-0.1 (-0.52%)

07:19
10/23/17
10/23
07:19
10/23/17
07:19
Initiation
Nightstar Therapeutics initiated  »

Nightstar Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PCH

Potlatch

$53.00

-0.35 (-0.66%)

07:18
10/23/17
10/23
07:18
10/23/17
07:18
Earnings
Potlatch reports Q3 EPS ex-items 94c, consensus 90c »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

PCH

Potlatch

$53.00

-0.35 (-0.66%)

07:18
10/23/17
10/23
07:18
10/23/17
07:18
Hot Stocks
Potlatch raises dividend to 40c per share from 37.5c per share »

Potlatch announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

SAIC

SAIC

$70.88

1.04 (1.49%)

07:18
10/23/17
10/23
07:18
10/23/17
07:18
Upgrade
SAIC rating change  »

SAIC upgraded to Buy from…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Dec

GGB

Gerdau

07:17
10/23/17
10/23
07:17
10/23/17
07:17
Initiation
Gerdau initiated  »

Gerdau resumed with a Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VALE

Vale

07:17
10/23/17
10/23
07:17
10/23/17
07:17
Initiation
Vale initiated  »

Vale resumed with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SCCO

Southern Copper

$43.13

-0.16 (-0.37%)

07:17
10/23/17
10/23
07:17
10/23/17
07:17
Initiation
Southern Copper initiated  »

Southern Copper resumed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FBR

Fibria Celulose

$16.24

0.45 (2.85%)

07:17
10/23/17
10/23
07:17
10/23/17
07:17
Initiation
Fibria Celulose initiated  »

Fibria Celulose resumed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PCH

Potlatch

$53.00

-0.35 (-0.66%)

, DEL

Deltic Timber

$89.12

0.98 (1.11%)

07:17
10/23/17
10/23
07:17
10/23/17
07:17
Hot Stocks
Mike Covey to continue to serve as chairman and CEO of combined Potlatch, Deltic »

The leadership team will…

PCH

Potlatch

$53.00

-0.35 (-0.66%)

DEL

Deltic Timber

$89.12

0.98 (1.11%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

  • 02

    Nov

GOOG

Alphabet

$988.20

3.75 (0.38%)

, GOOGL

Alphabet Class A

$1,005.07

3.23 (0.32%)

07:17
10/23/17
10/23
07:17
10/23/17
07:17
Periodicals
Google plans to share revenues with news publishers, FT reports »

Google is planning to…

GOOG

Alphabet

$988.20

3.75 (0.38%)

GOOGL

Alphabet Class A

$1,005.07

3.23 (0.32%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

  • 26

    Oct

  • 08

    Nov

  • 15

    Nov

  • 29

    Nov

  • 18

    Mar

BIIB

Biogen

$338.10

-4.32 (-1.26%)

07:16
10/23/17
10/23
07:16
10/23/17
07:16
Downgrade
Biogen rating change  »

Biogen downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

  • 25

    Oct

PCH

Potlatch

$53.00

-0.35 (-0.66%)

, DEL

Deltic Timber

$89.12

0.98 (1.11%)

07:15
10/23/17
10/23
07:15
10/23/17
07:15
Hot Stocks
Potlatch, Deltic Timber to combine in all-stock transaction »

Potlatch Corporation…

PCH

Potlatch

$53.00

-0.35 (-0.66%)

DEL

Deltic Timber

$89.12

0.98 (1.11%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

  • 02

    Nov

PSTI

Pluristem

$1.77

-0.035 (-1.94%)

07:15
10/23/17
10/23
07:15
10/23/17
07:15
Hot Stocks
Pluristem receives European patent covering PLX-R18 »

Pluristem Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

07:15
10/23/17
10/23
07:15
10/23/17
07:15
General news
FX Update: The dollar traded firmer »

FX Update: The dollar…

HAL

Halliburton

$43.33

-0.09 (-0.21%)

07:14
10/23/17
10/23
07:14
10/23/17
07:14
Hot Stocks
Halliburton CEO says 'North American business is hitting on all cylinders' »

"We had a strong…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.